Filgrastim
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Filgrastim: From Severe Congenital Neutropenia to Primary Release Disorder of Platelets
One-Sentence Summary
Filgrastim (recombinant G-CSF) was originally used to treat constitutional and severe congenital neutropenia, cyclic hematopoiesis, and chronic familial neutropenia. The TxGNN model predicts it may be effective for primary release disorder of platelets, but no clinical trials or publications currently support this prediction. This is a computational prediction only, with a weak mechanistic rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Constitutional neutropenia; severe congenital neutropenia; cyclic hematopoiesis; chronic familial neutropenia |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 99.998% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. From general knowledge, filgrastim is a G-CSF that binds the G-CSF receptor and stimulates the proliferation and differentiation of neutrophil progenitors. This explains its efficacy in neutropenic conditions.
Primary platelet release disorders are qualitative platelet function defects (impaired granule secretion). No established mechanistic link exists between G-CSF signaling and platelet granule release. The high TxGNN score likely reflects network proximity in the knowledge graph rather than a validated biological mechanism, so the prediction should be treated with caution.
Other top-ranked predictions are also platelet or coagulation-related conditions (pseudo-von Willebrand disease, Glanzmann thrombasthenia, Scott syndrome, and others). All are L5 with no supporting studies and no plausible mechanistic link to G-CSF. The only prediction with any linked trials is platelet-type bleeding disorder (rank 10), where the connection is indirect, via stem cell mobilization and transplant support.
Clinical Trial Evidence
Currently no related clinical trials are registered for primary release disorder of platelets.
For reference, the only predicted indication with linked trials is platelet-type bleeding disorder (rank 10). These seven trials are general stem cell transplant studies, mostly in hematologic malignancies, where filgrastim is a supportive component rather than the studied treatment. All were graded low relevance.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00296023 | NA | Completed | 25 | Low-dose allogeneic stem cell transplant for high-risk low-grade hematologic malignancies |
| NCT00004232 | Phase 1 | Completed | Not reported | CD34-enriched stem cells to augment bone marrow in allogeneic transplant |
| NCT00054236 | Phase 1 | Completed | 55 | Multiple cord blood unit transplant after non-myeloablative conditioning |
| NCT00301912 | Phase 2 | Withdrawn | 0 | Busulfan/fludarabine preparative regimen before matched unrelated donor transplant; no data |
| NCT00295997 | NA | Unknown | 35 | Non-myeloablative matched unrelated donor transplant |
| NCT00080925 | Phase 1 | Completed | 20 | T-cell depleted haploidentical transplant |
| NCT00004904 | Phase 1 | Completed | Not reported | T-cell depleted partially matched donor transplant with CD34 "veto" cells |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16267P | ACCOFIL 48 Solution for Injection or Infusion in a Pre-filled Syringe 48 MU/0.5 mL | Injection, solution | Not specified |
| SIN14196P | Nivestim 300mcg/0.5mL Solution for Injection/Infusion | Infusion, solution | Not specified |
| SIN10780P | NEUPOGEN Pre-filled Syringe 30 MU/0.5 mL | Injection | Not specified |
| SIN16268P | ACCOFIL 30 Solution for Injection or Infusion in a Pre-filled Syringe 30 MU/0.5 mL | Injection, solution | Not specified |
Safety Considerations
- Drug Interactions: 100 interactions were identified in the interaction database. The examples reviewed were all rated Moderate, and most are antineoplastic or radiopharmaceutical agents, including paclitaxel, mercaptopurine, azacitidine, bendamustine, alemtuzumab, arsenic trioxide, abemaciclib, ibritumomab tiuxetan, and iobenguane (I-131). The full list should be reviewed before any new use.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. There are no clinical trials or publications for primary release disorder of platelets, and no plausible link between G-CSF signaling and platelet granule release. Filgrastim is not a thrombopoietic agent.
To proceed, the following is needed:
- Mechanism of action data and a biologically plausible rationale linking G-CSF to platelet secretion
- Preclinical or clinical evidence in platelet function disorders
- Package insert warnings and contraindications from the HSA, to allow safety screening
- Approved indication text for the Singapore registrations
- If transplant-based strategies are of interest, a separate assessment of filgrastim's supportive role in stem cell mobilization for inherited platelet disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.